Sterling Capital Management LLC Lowers Stock Position in Roche Holding AG (OTCMKTS:RHHBY)

Sterling Capital Management LLC decreased its stake in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 7.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 90,064 shares of the company's stock after selling 7,512 shares during the period. Sterling Capital Management LLC's holdings in Roche were worth $3,174,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in RHHBY. Brooklyn Investment Group increased its position in shares of Roche by 36.6% in the fourth quarter. Brooklyn Investment Group now owns 1,354 shares of the company's stock valued at $48,000 after buying an additional 363 shares in the last quarter. Verity Asset Management Inc. increased its holdings in Roche by 26.8% during the 4th quarter. Verity Asset Management Inc. now owns 8,036 shares of the company's stock valued at $280,000 after acquiring an additional 1,697 shares in the last quarter. HighPoint Advisor Group LLC raised its position in Roche by 2.8% during the fourth quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company's stock worth $387,000 after acquiring an additional 304 shares during the last quarter. Confluence Investment Management LLC lifted its holdings in shares of Roche by 26.3% in the fourth quarter. Confluence Investment Management LLC now owns 13,981 shares of the company's stock valued at $488,000 after purchasing an additional 2,910 shares in the last quarter. Finally, SVB Wealth LLC acquired a new stake in shares of Roche in the fourth quarter valued at approximately $555,000.

Roche Price Performance

RHHBY traded up $0.32 during trading on Friday, hitting $38.90. The company's stock had a trading volume of 2,893,783 shares, compared to its average volume of 3,169,930. Roche Holding AG has a twelve month low of $29.20 and a twelve month high of $44.31. The firm's 50 day moving average price is $40.93 and its 200-day moving average price is $38.55. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. UBS Group raised Roche from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Morgan Stanley assumed coverage on Roche in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, Sanford C. Bernstein upgraded Roche to a "strong-buy" rating in a research report on Thursday, January 30th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Roche currently has a consensus rating of "Moderate Buy".

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.